IBJNews

Lilly receives Europe's OK for new Byetta use

Back to TopCommentsE-mailPrintBookmark and Share

European regulators have approved an expanded use for the diabetes treatment Byetta developed by drugmakers Amylin Pharmaceuticals Inc. and Eli Lilly and Co.

The companies said Friday they received approval for Byetta to be used with or without common treatments like metformin and Actos to treat adult type 2 diabetes patients who have not been able to control their blood sugar levels with just insulin. A panel advising the European Medicines Agency had recommended approval for the new use last month.

The FDA approved the same expanded use last fall.

San Diego-based Amylin and Indianapolis-based Lilly said patients taking Byetta with insulin achieved better blood sugar control without weight gain or an increased risk of their blood sugar levels dropping too low compared to patients using just insulin.

Byetta, or exenatide, is a twice-a-day injection. It was first approved in Europe in 2006.

Amylin and Lilly announced in November that they are ending their collaboration on Byetta and its successor, Bydureon, which is designed to be taken once per week. The two companies have already ended their partnership in the U.S., and Amylin will take over marketing of Byetta outside the U.S. by the end of 2013.

Shares of Lilly edged up 2 cents to $39.83 in early trading Friday, while Amylin's stock rose 8 cents to $15.49, paralleling slight gains made by the Nasdaq exchange.


ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT